ME03465B - Farmaceutska kompozicija s-ketamin hidrohlorida - Google Patents

Farmaceutska kompozicija s-ketamin hidrohlorida

Info

Publication number
ME03465B
ME03465B MEP-2019-229A MEP2019229A ME03465B ME 03465 B ME03465 B ME 03465B ME P2019229 A MEP2019229 A ME P2019229A ME 03465 B ME03465 B ME 03465B
Authority
ME
Montenegro
Prior art keywords
pharmaceutical composition
ketamine hydrochloride
ketamine
hydrochloride
pharmaceutical
Prior art date
Application number
MEP-2019-229A
Other languages
German (de)
English (en)
French (fr)
Inventor
Esther D G Basstanie
Johanna Bentz
Roger C A Embrechts
Nico Rudolph Niemeiijer
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME03465(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ME03465B publication Critical patent/ME03465B/me

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MEP-2019-229A 2013-03-15 2014-03-14 Farmaceutska kompozicija s-ketamin hidrohlorida ME03465B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361791505P 2013-03-15 2013-03-15
PCT/US2014/027074 WO2014143646A1 (en) 2013-03-15 2014-03-14 Pharmaceutical composition of s-ketamine hydrochloride
EP14719471.6A EP2968221B1 (en) 2013-03-15 2014-03-14 Pharmaceutical composition of s-ketamine hydrochloride

Publications (1)

Publication Number Publication Date
ME03465B true ME03465B (me) 2020-01-20

Family

ID=50549465

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-229A ME03465B (me) 2013-03-15 2014-03-14 Farmaceutska kompozicija s-ketamin hidrohlorida

Country Status (26)

Country Link
US (2) US20140275277A1 (me)
EP (3) EP3498268A1 (me)
KR (3) KR20210028278A (me)
CN (3) CN105073103A (me)
AU (6) AU2014228324B2 (me)
CL (1) CL2015002733A1 (me)
CR (1) CR20150480A (me)
CY (1) CY1121928T1 (me)
DK (1) DK2968221T3 (me)
ES (1) ES2745024T3 (me)
HR (1) HRP20191477T1 (me)
HU (1) HUE045982T2 (me)
LT (1) LT2968221T (me)
ME (1) ME03465B (me)
MX (2) MX386479B (me)
MY (2) MY203693A (me)
NZ (1) NZ712270A (me)
PE (2) PE20160052A1 (me)
PH (2) PH12021552333A1 (me)
PL (1) PL2968221T3 (me)
PT (1) PT2968221T (me)
RS (1) RS59130B1 (me)
SG (3) SG10201912735TA (me)
SI (1) SI2968221T1 (me)
SM (1) SMT201900472T1 (me)
WO (1) WO2014143646A1 (me)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2897453T3 (es) 2013-09-13 2022-03-01 Univ Chiba Nat Univ Corp Aplicación de R-ketamina y sal de la misma como productos farmacéuticos
WO2015108985A1 (en) * 2014-01-14 2015-07-23 Children's Hospital Medical Center Compositions comprising ketamine for treating an autism spectrum disorder
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
CN106562952B (zh) * 2015-10-09 2020-06-09 江阴安博生物医药有限公司 氯胺酮在治疗重性抑郁障碍中的应用
CA3059775A1 (en) * 2017-04-13 2018-10-18 Ovid Therapeutics Inc. Methods of treating developmental encephalopathies
WO2018234568A2 (en) * 2017-06-23 2018-12-27 Develco Pharma Schweiz Ag Hydroxynorketamine for the use in the treatment of depression
PT3505157T (pt) 2017-12-29 2022-02-18 Celon Pharma Sa Composição de cetamina em pó seco para administração pulmonar em depressão resistente ao tratamento
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
JP2021523228A (ja) 2018-05-04 2021-09-02 パーセプション ニューロサイエンス,インコーポレイティド 物質乱用の治療方法
PL3628313T3 (pl) 2018-09-28 2025-06-23 Novohale Therapeutics, Llc Kompozycja ketaminy do zastosowania w sposobie leczenia depresji przez podawanie dopłucne
US20220062200A1 (en) * 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
PL3976145T3 (pl) 2019-05-31 2025-04-28 Celon Pharma S.A. Inhalator do elektronicznie nadzorowanego pozajelitowego podawania kompozycji farmaceutycznej
EP3977469A1 (en) 2019-05-31 2022-04-06 Celon Pharma S.A. Electronically supervised administration of a pharmaceutical composition
AU2020345050A1 (en) * 2019-09-13 2021-09-16 Janssen Pharmaceuticals, Inc. Intranasal administration of esketamine
US11160799B2 (en) * 2019-10-22 2021-11-02 Cessatech A/S Pediatric combination
TW202135787A (zh) * 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
PH12022550775A1 (en) * 2019-12-20 2023-08-23 Alar Pharmaceuticals Inc Long-acting injectable formulations of ketamine pamoate salts
CN114903840A (zh) * 2021-02-08 2022-08-16 四川普锐特药业有限公司 一种治疗抑郁症的低剂量r-氯胺酮经鼻药物
CN113813250B (zh) * 2021-07-21 2023-05-05 广州新济药业科技有限公司 含氯胺酮的药物组合物及其制备方法和应用
EP4480473A4 (en) * 2022-04-26 2025-06-04 Yichang Humanwell Pharmaceutical Co., Ltd. LIQUID ESKETAMINE PREPARATION AND USE THEREOF
JP2025513273A (ja) 2022-04-26 2025-04-24 イーチャン・ヒューマンウェル・ファーマシューティカル・カンパニー・リミテッド エスケタミン液体製剤及びその使用
WO2024123935A2 (en) * 2022-12-07 2024-06-13 Freedom Biosciences, Inc. Treatment or prevention of depressive disorders through combination therapy
WO2025037252A1 (en) * 2023-08-14 2025-02-20 Javitt Daniel C Compositions and methods for treatment of chronic pain and depression
US12005035B1 (en) * 2023-08-14 2024-06-11 Daniel C. Javitt Compositions and methods for treatment of chronic pain and depression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4312016A1 (de) * 1993-04-13 1994-10-20 Goedecke Ag Stabile Ketamin-Lösungen
US6572849B2 (en) * 2000-09-20 2003-06-03 Lee Shahinian, Jr. Self-preserved antibacterial nasal, inhalable, and topical ophthalmic preparations and medications
US6881731B1 (en) 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
AU2007229866A1 (en) 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
DE102007009888A1 (de) * 2007-02-28 2008-09-04 Hermann, Holger Lars, Dr. Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen
EP2887930A4 (en) * 2012-08-23 2016-03-23 Stuart L Weg ANXIOLYTIC COMPOSITION, FORMULATION AND METHOD OF USE

Also Published As

Publication number Publication date
MX2015012342A (es) 2016-06-06
PL2968221T3 (pl) 2020-01-31
CL2015002733A1 (es) 2016-03-04
SI2968221T1 (sl) 2019-08-30
SMT201900472T1 (it) 2019-09-09
PT2968221T (pt) 2019-09-13
CN111297803A (zh) 2020-06-19
AU2019200702A1 (en) 2019-02-21
MY203693A (en) 2024-07-14
KR20210028278A (ko) 2021-03-11
US20140275276A1 (en) 2014-09-18
AU2019200696B2 (en) 2020-10-08
SG10201802106TA (en) 2018-04-27
BR112015022970A2 (pt) 2017-07-18
MX386479B (es) 2025-03-18
PH12021552333A1 (en) 2022-08-01
AU2014228324B2 (en) 2019-01-31
AU2023200976B2 (en) 2025-03-27
AU2019200705A1 (en) 2019-02-21
AU2014228324A1 (en) 2015-09-17
EP4309735A3 (en) 2024-04-17
EP2968221A1 (en) 2016-01-20
EP4309735A2 (en) 2024-01-24
MX373678B (es) 2020-06-26
AU2019200705B2 (en) 2020-10-08
AU2021200072A1 (en) 2021-03-18
BR112015022970A8 (pt) 2019-11-26
CN105073103A (zh) 2015-11-18
RS59130B1 (sr) 2019-09-30
HRP20191477T1 (hr) 2019-12-13
AU2023200976A1 (en) 2023-03-23
KR20230156807A (ko) 2023-11-14
PH12015501957A1 (en) 2016-01-11
EP3498268A1 (en) 2019-06-19
ES2745024T3 (es) 2020-02-27
HUE045982T2 (hu) 2020-01-28
AU2019200696A1 (en) 2019-02-21
NZ712270A (en) 2020-02-28
WO2014143646A1 (en) 2014-09-18
CR20150480A (es) 2015-10-26
DK2968221T3 (da) 2019-08-05
MY191332A (en) 2022-06-16
US20140275277A1 (en) 2014-09-18
EP2968221B1 (en) 2019-06-19
PE20160052A1 (es) 2016-01-28
AU2019200702B2 (en) 2020-10-08
SG10201912735TA (en) 2020-02-27
SG11201507358VA (en) 2015-10-29
CN116251084A (zh) 2023-06-13
PE20191796A1 (es) 2019-12-24
CY1121928T1 (el) 2020-10-14
LT2968221T (lt) 2019-07-25
KR20150129023A (ko) 2015-11-18

Similar Documents

Publication Publication Date Title
FR21C1059I2 (fr) Compositions pharmaceutiques
LT2968221T (lt) S-ketamino hidrochlorido farmacinė kompozicija
PT3030262T (pt) Composição farmacêutica de associação
SG11201507347QA (en) Pharmaceutical composition of s-ketamine hydrochloride
DK3256138T3 (da) Farmaceutiske sammensætninger omfattende meloxicam
HRP20180684T1 (hr) Kombinacija lijekova
LT3080100T (lt) Lizinui specifinės demetilazės-1 inhibitoriai
LT2981255T (lt) Empagliflozino terapiniai panaudojimo būdai
HRP20190101T1 (hr) Terapeutske uporabe empagliflozina
EP2889350A4 (en) ADHESIVE COMPOSITION
DK2968214T3 (da) Hidtil ukendte analgetiske sammensætninger
EP2958994A4 (en) Vaccine composition
DK3027750T3 (da) Biokatalytisk sammensætning
DK2897594T3 (da) Farmaceutisk sammensætning
DK2988733T3 (da) Farmaceutisk sammensætning indeholdende krystallin macitentan
IL242220A0 (en) Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
DK3079667T3 (da) Farmaceutiske doseringsformer
DK3003401T3 (da) Farmaceutisk præparat
EP2988734C0 (en) FORMULATION OF A HARD CAPSULE
BR112015002646A2 (pt) composto e composição farmacêutica
EP3043648C0 (en) PHARMACEUTICAL COMPOSITIONS OF BENDAMUSTINE
HRP20182110T1 (hr) Sastav spojeva tiakumicina
DK3060213T3 (da) Farmaceutiske sammensætninger omfattende antibakterielle midler
PL2956129T3 (pl) Kompozycje farmaceutyczne zawierające deksketoprofen i tramadol
TH1501001236A (th) องค์ประกอบทางเภสัชกรรมซึ่งประกอบด้วย รีโกราเฟนิบ ที่ถูกเคลือบ